Cutler Whitely is a biotech venture builder operating at the intersection of advanced therapeutics, medtech, and commercialization strategy.

​

He currently serves as a Launchpad Commercialization Associate at LifeX and as Head of Commercialization & Strategy for Myosthenos, a translational biotechnology company developing first-in-class small molecule therapeutics for RYR1-related myopathies. Myosthenos was selected as a finalist in Nucleate New York's Activator Program and received Ipsen's globally evaluated First-in-Class Award — recognizing breakthrough science with clear partnership potential. His work focuses on market architecture, indication prioritization, capital strategy, and investor-facing execution — building the bridge from lab discovery to scalable enterprise.

​

Cutler's background spans the full stack of biotech innovation:

• Industry drug discovery at Novartis Institutes for BioMedical Research in early-stage cancer therapeutics

• MedTech venture leadership as Head of R&D and Product Development at Astellar Labs

• Contract research and manufacturing strategy in business development at Apeloa Pharmaceuticals

• Academic research and clinical science at Penn Medicine, Thomas Jefferson University Hospitals, and Drexel University College of Medicine
   

He earned a Master of Science in Biotechnology (4.0 GPA) from Brown University, where his thesis focused on active targeting antifungal drug delivery systems and commercialization strategy. He holds an MBA from Columbia Business School.

​

Cutler grew up in rural Pennsylvania in a blue-collar family — and before biotech, competed internationally on the World Snowboard Tour. That background shaped something that doesn't show up on a CV: a grounded, operational mindset, comfort with uncertainty, and the discipline to execute when the outcome isn't guaranteed.

​

His focus today is building durable biotechnology platforms that translate complex science into measurable impact — combining technical fluency with capital discipline and commercialization rigor. He is equally attuned to how frontier biotechnologies intersect with national security and U.S. competitiveness, and the role science-driven companies can play in strengthening both.